Nascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.09 USD | -7.77% | -9.82% | -47.95% |
1st Jan change | Capi. | |
---|---|---|
-47.95% | 15.35M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.64% | 22.28B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- NBIO Stock
- News Nascent Biotech, Inc.
- Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer